Hertz Posts Worse-Than-Expected Loss as Smaller Fleet Hits Sales
Hertz Global Holdings Inc. posted a larger-than-expected loss in the first quarter as the rental company shrank its fleet of cars and some customers slowed bookings.
Revenue fell 13% in the period, contributing to an adjusted loss of $1.12 per share, the company said in a statement Monday. Analysts had expected a 99-cent deficit on average, according to estimates compiled by Bloomberg.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Allane Full Year 2024 Earnings: €1.90 loss per share (vs €0.43 profit in FY 2023)
Revenue: €750.8m (up 21% from FY 2023). Net loss: €39.2m (down from €8.85m profit in FY 2023). €1.90 loss per share (down from €0.43 profit in FY 2023). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 1.1% growth forecast for the Transportation industry in Europe. Performance of the market in Germany. The company's shares are up 11% from a week ago. Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Allane (1 shouldn't be ignored) you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Down 36%, is this US growth stock about to surge again?
US growth stocks have largely been on a stellar run since the start of 2023. That certainly has been the case with Cellebrite DI (NASDAQ:CLBT), climbing by over 480% and reaching an all-time high in February. Yet since then, its performance has slipped a bit. Its 2024 fourth-quarter earnings missed the mark, as did its subsequent 2025 first-quarter results. And while the miss was small, growth inventors tend to be quite unforgiving towards businesses trading at lofty valuations. So seeing a 36% pullback from its February highs isn't a major surprise. However, with the stock now trading at a cheaper price, could this be a buying opportunity? As a quick crash course, Cellebrite specialises in digital forensics. In the corporate world, this technology can be handy when investigating cybersecurity breaches. But for the most part, demand for Cellebrite's technology actually comes from law enforcement agencies. An estimated 90% of crime today has some sort of digital element. As such, requests to decrypt mobile phones and other electronic devices used to commit crimes are creating a significant backlog for investigators and prosecutors – a migraine-level problem that Cellebrite is helping solve. Digging into the latest results, revenue growth continues to be explosive at 20% year-on-year, with annual recurring revenues climbing by 23% to $408m. And with a net retention rate of 121%, customers are clearly finding value in Cellebrite's technology as they're seemingly happy to ramp up spending each year. Sadly, that just wasn't enough to sate the appetite of growth investors who expected a little more top-line growth. And with management forecasting that sales might only grow by 17% for the full year of 2025, the stock endured a bit of a tumble. Even after its recent valuation hit, at a price-to-sales ratio of 8.8, Cellebrite shares can hardly be described as cheap. Yet projections from some analysts suggest that the premium might be worth paying. For example, JPMorgan currently has a share price target of $28 – around 70% higher than today's price. Such large 12-month projections should always be taken with a grain of salt. But Cellebrite's target market is expected to grow at a near-15% annualised rate over the next five years. And given the company's already the top dog in the sector, we might still be in the early days of Cellebrite's growth story – even more so now that profits have started to materialise. Having said that, there's no denying the high risk here. Cellebrite's technology is a powerful tool that can be easily abused if it gets into the wrong hands. This reputational risk is already being put to the test with reports of authoritarian regimes using the technology in human rights violations. Management's already tackling these issues with much stricter customer screening, disabling access when misuse is detected, as well as proactively suspending sales in over 60 countries. Nevertheless, ethical concerns will undoubtedly persist. Despite this risk, I remain an optimist. The valuation's still on the pricey side. But I think the premium might be worth paying, considering the opportunity that Cellebrite's seeking to capitalise on. That's why I've already used the recent stock price weakness to build a small position in my growth portfolio. The post Down 36%, is this US growth stock about to surge again? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Zaven Boyrazian has positions in Cellebrite. The Motley Fool UK has recommended Cellebrite. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Those who invested in FRoSTA (FRA:NLM) five years ago are up 67%
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses is one path to excess returns. For example, the FRoSTA Aktiengesellschaft (FRA:NLM) share price is up 44% in the last 5 years, clearly besting the market return of around 18% (ignoring dividends). However, more recent returns haven't been as impressive as that, with the stock returning just 37% in the last year, including dividends. So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. Over half a decade, FRoSTA managed to grow its earnings per share at 28% a year. This EPS growth is higher than the 8% average annual increase in the share price. So it seems the market isn't so enthusiastic about the stock these days. You can see how EPS has changed over time in the image below (click on the chart to see the exact values). We know that FRoSTA has improved its bottom line lately, but is it going to grow revenue? This free report showing analyst revenue forecasts should help you figure out if the EPS growth can be sustained. When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. In the case of FRoSTA, it has a TSR of 67% for the last 5 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the total shareholder return. It's nice to see that FRoSTA shareholders have received a total shareholder return of 37% over the last year. That's including the dividend. That's better than the annualised return of 11% over half a decade, implying that the company is doing better recently. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. Is FRoSTA cheap compared to other companies? These 3 valuation measures might help you decide. For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on German exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
